Lotan Y - Search Results

1

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S, Timmerman R. Boike TP, et al. Among authors: lotan y. J Clin Oncol. 2011 May 20;29(15):2020-6. doi: 10.1200/JCO.2010.31.4377. Epub 2011 Apr 4. J Clin Oncol. 2011. PMID: 21464418 Free PMC article. Clinical Trial.

2

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.

Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM. Lotan Y, et al. J Clin Oncol. 2005 Mar 20;23(9):1911-20. doi: 10.1200/JCO.2005.03.137. J Clin Oncol. 2005. PMID: 15774783 Review.

3

Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.

Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI. Lotan Y, et al. J Clin Oncol. 2005 Sep 20;23(27):6533-9. doi: 10.1200/JCO.2005.05.516. Epub 2005 Aug 22. J Clin Oncol. 2005. PMID: 16116151

4

Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model.

Lotan Y, Stanfield J, Cho LC, Sherwood JB, Abdel-Aziz KF, Chang CH, Forster K, Kabbani W, Hsieh JT, Choy H, Timmerman R. Lotan Y, et al. J Urol. 2006 May;175(5):1932-6. doi: 10.1016/S0022-5347(05)00893-1. J Urol. 2006. PMID: 16600801

5

Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model.

Walsh L, Stanfield JL, Cho LC, Chang CH, Forster K, Kabbani W, Cadeddu JA, Hsieh JT, Choy H, Timmerman R, Lotan Y. Walsh L, et al. Among authors: lotan y. Eur Urol. 2006 Oct;50(4):795-800; discussion 800. doi: 10.1016/j.eururo.2006.03.021. Epub 2006 Mar 29. Eur Urol. 2006. PMID: 16632182

6

The cost of prostate cancer chemoprevention: a decision analysis model.

Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Svatek RS, et al. Among authors: lotan y. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1485-9. doi: 10.1158/1055-9965.EPI-06-0221. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16896037

7

Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.

Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Shariat SF, et al. Among authors: lotan y. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5377-84. doi: 10.1158/1078-0432.CCR-07-0330. Clin Cancer Res. 2007. PMID: 17875766

8

Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.

Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Svatek RS, et al. Among authors: lotan y. Cancer. 2008 Mar 1;112(5):1058-65. doi: 10.1002/cncr.23276. Cancer. 2008. PMID: 18186497 Free article.

9

Sirolimus in metatastic renal cell carcinoma.

Brugarolas J, Lotan Y, Watumull L, Kabbani W. Brugarolas J, et al. Among authors: lotan y. J Clin Oncol. 2008 Jul 10;26(20):3457-60. doi: 10.1200/JCO.2008.16.4590. J Clin Oncol. 2008. PMID: 18612163 No abstract available.

10

Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.

Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Gupta A, et al. Among authors: lotan y. Clin Cancer Res. 2008 Nov 15;14(22):7385-90. doi: 10.1158/1078-0432.CCR-07-5110. Clin Cancer Res. 2008. PMID: 19010854

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

771 results

Search Page

Filters